

## PROGRAMMA NEDERLANDSE NEFROLOGIEDAGEN 2004

### DONDERDAG 25 MAART 2004

- 08.30-10:00**    **Ontvangst en inschrijving / Centrale ontvangthal**
- 10.00-12.00**    **LVDT Algemene Ledenvergadering / Brabantzaal**
- 10.00-12.00**    **VDT programma / zaal 81**
- 10.00-13.00**    **DNN Algemene Ledenvergadering / zaal 80**
- 10.00-12.00**    **“Klinische Wetenschappelijk Programma” / Diezahal**  
*voorzitters: M. van Buren en P.J. Blankestijn*
- 10.00-10.30    J.G. v.d. Hoeven (Nijmegen)  
Metabole acidose bij IC-patienten
- 10.30-11.00    P.E. de Jong (Groningen)  
From secondary to primary prevention of progressive renal disease: the case for screening on albuminuria
- 11.00-11.30    P.H.A. Gaede (Kopenhagen, DK)  
Multifactorial intervention to prevent cardiovascular disease: experience in diabetic patients
- 11.30-12.00    N. Wright (Londen, UK)  
Stem cells and the kidney - intra-renal and extra-renal approaches to kidney regeneration and repair
- 10.00-12:00**    **Fundamenteel Wetenschappelijk Symposium I / Baroniezaal**  
**“Lessons from cell and animal models”**  
*voorzitters: R.J.M. Bindels en E. de Heer*
- 10.00-10.40    P. M. Mathieson (Bristol, UK)  
The new world of podocyte
- 10.40-11.20    F. Strutz (Gottingen, GE)  
Epithelial-mesenchymal transition and the reversal of renal fibrogenesis
- 11.20-12.00    S. Quaggin (Toronto, CA)  
Conditional gene targeting in the kidney: new insights into glomerular development and disease
- 12.00-13.30**    **LUNCH / Kempenhal en Genderhal**
- 12.00-12.45**    **NfN Huishoudelijke Algemene Vergadering / Diezahal**

**12.00-13.00 “Carrière planning voor de AIO en jonge postdocs” / Baroniezaal**  
voorzitters: *J.C. Korevaar en D. Huugen*

12.00-12.20 J. Hoenderop (Nijmegen)  
Ervaringen van een ex-AIO

12.20-12.40 B. de Galan (Nijmegen)  
Ervaringen van een ex-AGIKO

12.40-13.00 M. Brandsma (Den Haag)  
Een VENI-aanvraag indienen bij ZonMw

**13.30- 17.40 VDT programma / zaal 81**

**13.30-14:00 Klinisch Pathologische Conferentie / Diezahal**  
voorzitters: *G.J. Navis en K.M.L. Leunissen*  
J.J. Weening en R. Krediet (Amsterdam)

**14.05-15.32 Wetenschappelijke Sessie NfN I / Diezahal**  
voorzitters: *A.W.L. v.d. Wall Bake en R. Zietse*

14.05-14.17 1. Determinants of renal function in the general population  
*J.C. Verhave<sup>1</sup>, H.L. Hillege<sup>2</sup>, J.G.M. Burgerhof<sup>3</sup>, R.T. Gansevoort<sup>1</sup>, D. de Zeeuw<sup>4</sup>, P.E. de Jong<sup>1</sup>*  
<sup>1</sup>Nephrology, UMC Groningen, <sup>2</sup>Cardiology, UMC Groningen, <sup>3</sup>Epidemiology & Statistics, UMC Groningen, <sup>4</sup>Clinical Pharmacology, UMC Groningen

14.17-14.29 2. ACE polymorphism and renal function  
*RC Özsoy<sup>1</sup>, S Rombach<sup>1</sup>, JC Korevaar<sup>1</sup>, JC Defesche<sup>2</sup>, MG Koopman<sup>1</sup>*  
<sup>1</sup>Department of Nephrology, <sup>2</sup>Department of Vascular Medicine, The Academic Medical Center, University of Amsterdam

14.29-14.41 3. Altered activity of plasma hemopexin in patients with minimal change disease.  
*W.W.Bakker<sup>1</sup>, C.M.L.van Dael<sup>2</sup>, C.J.W.M.Pierik<sup>2</sup>, J.A.E.van Wijk<sup>3</sup>, J.Nauta<sup>4</sup>, R.M.Jongman<sup>1</sup>, T.Borghuis<sup>1</sup>*  
<sup>1</sup>Pathology and Lab. Medicine, AZG, <sup>2</sup>Department of Pediatrics, AZG, <sup>3</sup>Department of Pediatrics, VUMC, <sup>4</sup>Sophia Childrens Hospital, Rotterdam

14.41-14.53 4. Is azathioprine an alternative for cyclophosphamide in the treatment of patients with proliferative lupus nephritis? Two-year results of the Dutch Lupus Nephritis Study I.  
*C. Grootsholten<sup>1</sup>, G. Ligtenberg<sup>2</sup>, E.C. Hagen<sup>3</sup>, A.W.L. van den Wall Bake<sup>4</sup>, J.W. de Glas-Vos<sup>5</sup>, M. Bijl<sup>6</sup>, J.C. van Houwelingen<sup>7</sup>, R.W.H.M. Derksen<sup>2</sup>, J.H.M. Berden<sup>1</sup>, on behalf of the Dutch Working Party for SLE*  
<sup>1</sup>UMC St Radboud Nijmegen, <sup>2</sup>UMC Utrecht, <sup>3</sup>Meander Medisch Centrum Amersfoort, <sup>4</sup>Máxima Medisch Centrum Veldhoven, <sup>5</sup>Academisch Medisch Centrum Amsterdam, <sup>6</sup>Academisch Ziekenhuis Groningen, <sup>7</sup>Leids Universitair Medisch Centrum

14.53-15.05 5. Dendritic cell function amongst hepatitis B vaccination non-responders in patients on chronic hemodialysis  
*M.A. Verkade, C. van Druningen, L.M.B. Vaessen, W. Weimar, M.G.H. Betjes*  
Department of Nephrology, Erasmus MC

15.05-15.17 6. Elevated levels of the T cell activation marker sIL-2R predict relapse in PR3-ANCA associated vasculitis  
*J.S.F. Sanders, M.G. Huitema, C.G.M. Kallenberg, C.A. Stegeman*  
University Hospital Groningen

- 15.17-15.32 7. Do biopsy scores at diagnosis explain differences in outcome in ANCA-associated vasculitis?  
*M.C. Slot, P. van Paassen, P.J.C. van Breda Vriesman, J.W. Cohen Tervaert*  
 Academisch ziekenhuis Maastricht
8. Early presence of markers of atherosclerosis in ANCA-associated vasculitis  
*M.C. Slot, R. Theunissen, P. van Paassen, P.J.C. van Breda Vriesman, J.G.M.C. Damoiseaux, J.W. Cohen Tervaert*  
 Academisch ziekenhuis Maastricht

**14.05-15.29 Wetenschappelijke Sessie NfN II / Zaal 80**

voorzitters: *B. Braam en J. Joles*

- 14.05-14.17 9. Renal calcium wasting in mice lacking the epithelial calcium channel TRPV5  
*J.G.J. Hoenderop<sup>1</sup>, J.P.T.M. van Leeuwen<sup>2</sup>, B.C.J. van der Eerden<sup>2</sup>, F.F.J. Kersten<sup>1</sup>, A.W.C.M. van der Kemp<sup>1</sup>, A. Merillat<sup>3</sup>, J.H. Waarsing<sup>5</sup>, B.C. Rossier<sup>3</sup>, V. Vallon<sup>4</sup>, E. Hummler<sup>3</sup>, R.J.M. Bindels<sup>1</sup>,*  
<sup>1</sup>Physiology, UMC Nijmegen, NL, <sup>2</sup>Internal Medicine, EMC Rotterdam, NL, <sup>3</sup>Pharmacology, Lausanne, CH, <sup>4</sup>Pharmacology, Tübingen, D, <sup>5</sup>Orthopaedics, EMC Rotterdam, NL
- 14.17-14.29 10. Adverse effects of ACEi on renal vasculature and interstitium: effects of sodium status  
*I.Hamming, G.J.Navis, H.van Goor*  
 Kidney Center, AZG
- 14.29-14.41 11. Low Dietary Sodium Enhances Plasma Angiotensin-(1-7) Levels During ACE Inhibition in Healthy Volunteers  
*A.T. Lely<sup>1</sup>, M.J.A. Kocks<sup>1</sup>, F. Boomsma<sup>2</sup>, P.E. de Jong<sup>1</sup>, G.J. Navis<sup>1</sup>*  
<sup>1</sup>UMC, Groningen, <sup>2</sup>Erasmus MC, Rotterdam
- 14.41-14.53 12. (Pro)renin induces gene transcription in cardiomyocytes independent of angiotensin-II  
*J.J. Saris<sup>1</sup>, P.A.C. 't Hoen<sup>2</sup>, G. Nguyen<sup>3</sup>, A..H.J. Danser<sup>1</sup>*  
<sup>1</sup>Farmacologie, Erasmus MC, <sup>2</sup>Humane Genetica, LUMC, <sup>3</sup>INSERM U-489, Paris, Frankrijk
- 14.53-15.05 13. Rescue of the cell surface expression of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus  
*J.H. Robben, N.V.M. Knoers, P.M.T. Deen*  
 UMC St.Radboud, Nijmegen
- 15.05-15.17 14. The novel Aquaporin binding protein 1 reduces the rate of Aquaporin-2 water channel synthesis through a coiled-coil interaction with the proximal region of its C-terminal tail  
*Bas W.M. van Balkom<sup>1</sup>, Giel Hendriks<sup>2</sup>, Erik-Jan Kamsteeg<sup>1</sup>, Fabrizio de Mattia<sup>1</sup>, Anne van der Voorde<sup>2</sup>, Francois van Herp<sup>3</sup>, Peter van der Sluijs<sup>2</sup>, Peter M.T. Deen<sup>1</sup>*  
<sup>1</sup>Dept Physiology, UMC Nijmegen, <sup>2</sup>Dept Cell Biology, UMC Utrecht, <sup>3</sup>Dept Mol. An. Physiology, KUNijmegen
- 15.17-15.32 15. Mono-ubiquitination and missorting to lysosomes of the Aquaporin-2 water channel mutant AQP2-E258K explains dominant Nephrogenic Diabetes Insipidus  
*Erik-Jan Kamsteeg<sup>1</sup>, Paul JM Savelkoul<sup>1</sup>, Irene BM Konings<sup>1</sup>, Peter van der Sluijs<sup>2</sup>, Peter MT Deen<sup>1</sup>*  
<sup>1</sup>Dept Physiology, UMC Nijmegen, <sup>2</sup>Dept Cell Biology, UMC Utrecht
16. A novel cellular phenotype in recessive Nephrogenic Diabetes Insipidus: retention signal of AQP2-P262L is overruled by apical targeting signals of wild-type Aquaporin-2 after formation of heterotetramers  
*Erik-Jan Kamsteeg<sup>1</sup>, Fabrizio de Mattia<sup>1</sup>, Paul JM Savelkoul<sup>1</sup>, Daniel Bichet<sup>2</sup>, Irene BM Konings<sup>1</sup>, Nannette Marr<sup>1</sup>, Marie-Françoise Arthus<sup>2</sup>, Michèle Lonergan<sup>2</sup>, Peter van der Sluijs<sup>3</sup>, Gary Robertson<sup>4</sup>, Peter MT Deen<sup>1</sup>*

<sup>1</sup> Dept Physiology, UMC Nijmegen, <sup>2</sup> Centre de Recherche, Montreal, Canada, <sup>3</sup> Dept Cell Biology, UMC Utrecht, <sup>4</sup> Northwestern University, Chicago, USA

**14.05-15.29 Wetenschappelijke Sessie NfN III / Baroniezaal**

voorzitters: R. Goldschmeding en J. van der Vlag

- 14.05-14.17 17. Upregulation of connective tissue growth factor (CTGF) plasma levels in plasma, urine and renal tissue of mice with streptozotocin-induced diabetes mellitus  
*P. Roestenberg<sup>1</sup>, P. Martens<sup>2</sup>, J. Joles<sup>2</sup>, C. Trischberger<sup>1</sup>, N. Oliver<sup>3</sup>, W. Usinger<sup>3</sup>, F. van Nieuwenhoven<sup>1</sup>, R. Goldschmeding<sup>1</sup>*  
<sup>1</sup> Department of Pathology, UMC Utrecht, <sup>2</sup> Department of Nephrology, UMC Utrecht, <sup>3</sup> Fibrogen, Inc., South San Francisco, USA
- 14.17-14.29 18. Renal cortical and glomerular message for VEGF is decreased but that for TGF- $\beta$  is unaltered in human diabetic nephropathy  
*J.J. Baelde<sup>1</sup>, M. Eikmans<sup>1</sup>, D.W.P. Lappin<sup>2</sup>, P.P. Doran<sup>2</sup>, H.R. Brady<sup>2</sup>, E de Heer<sup>1</sup>, J.A. Bruijn<sup>5</sup>*  
<sup>1</sup> Department of Pathology, Leiden University, <sup>2</sup> University College Dublin, Dublin, Ireland
- 14.29-14.41 19. Early inactivation of transforming growth factor (TGF $\beta$ 1) by decorin during the induction of anti-Thy-1 nephritis in Lew/Maa rats exacerbates, late inactivation ameliorates renal disease.  
*J.A. Aben<sup>1</sup>, J.J. Baelde<sup>1</sup>, A.M. van der Wal<sup>1</sup>, N.A. Noble<sup>2</sup>, W.A. Border<sup>2</sup>, J.A. Bruijn<sup>1</sup>, E. de Heer<sup>1</sup>*  
<sup>1</sup> Dept. of Pathology, LUMC, Leiden, <sup>2</sup> Institute of fibrosis Research, Ut, USA
- 14.41-14.53 20. Expression of transforming growth factor-beta in follow-up kidney protocol biopsies is not different between renal transplant patients receiving cyclosporine-based and tacrolimus-based immunosuppressive regimens  
*M. C. Roos-van Groningen<sup>1</sup>, J. J. Baelde<sup>1</sup>, E. M. Scholten<sup>2</sup>, I. M. Bajema<sup>1</sup>, S. Florquin<sup>3</sup>, A. T. Rowshani<sup>3</sup>, E. de Heer<sup>1</sup>, J. W. de Fijter<sup>2</sup>, J. A. Bruijn<sup>1</sup>, M. Eikmans<sup>1</sup>*  
<sup>1</sup> Dpt. of Pathology, LUMC, Leiden, <sup>2</sup> Dpt. of Nephrology, LUMC, Leiden, <sup>3</sup> Dpt. of Pathology, AMC, Amsterdam
- 14.53-15.05 21. Substrain-selective glomerular expression of neuronal activity-regulated pentraxin (NARP) discriminates between remodeling and progression towards glomerulosclerosis after induction of anti-Thy-1 nephritis (ATN) in rats  
*L. Bai<sup>1</sup>, J.A. Aben<sup>1</sup>, J.J. Baelde<sup>1</sup>, A.M. van der Wal<sup>1</sup>, N.A. Noble<sup>2</sup>, J.A. Bruijn<sup>1</sup>, E. de Heer<sup>1</sup>*  
<sup>1</sup> Dept. of Pathology, LUMC, Leiden, <sup>2</sup> Institute of fibrosis Research, Ut, USA
- 15.05-15.17 22. Osteopontin upregulation during development of proteinuria-induced renal damage  
*A.B. Kramer<sup>1</sup>, S.D. Ricardo<sup>2</sup>, D.J. Kelly<sup>3</sup>, F. Waanders<sup>1</sup>, H. van Goor<sup>1</sup>, G.J. Navis<sup>1</sup>*  
<sup>1</sup> Kidney Center, Acad Ziekenhuis Groningen, <sup>2</sup> Monash University, Melbourne, Australië, <sup>3</sup> St Vincents Hospital Melbourne, Australië
- 15.17-15.29 23. Renal Advanced Glycation End Products in Non-Diabetic Proteinuria-Induced Renal Damage in Rat  
*F. Waanders<sup>1</sup>, W.L. Greven<sup>1</sup>, J.W. Baynes<sup>2</sup>, S.R. Thorpe<sup>2</sup>, A.B. Kramer<sup>1</sup>, H. van Goor<sup>1</sup>, G.J. Navis<sup>1</sup>*  
<sup>1</sup> Kidney Centre, Groningen, <sup>2</sup> Dept. of Biochemistry, Columbia SC, USA

**14.05-15.20 Paramedische sessie I / Brabantzaal**

voorzitters: Y. de Koter en R. Tollenaar

- 14.05-14.20 24. Project Vaattoegang Nederlandse Werkgroep Vaattoegang: stand van zaken

*Natascha Beukers, Magda van Loon, Wil van der Mark, Peter Blankestijn, Cor de Bruin, Roel Huisman, Frank van der Sande, Jan Tordoir, Jan Zijlstra*  
Nierstichting Nederland; Nederlandse Werkgroep Vaattoegang

- 14.20-14.35 25. Implementeren van gestructureerde vaattoegangszorg  
*Etienne Hoekstra*  
Viecuri; Medisch Centrum voor Noord- Limburg
- 14.35-14.50 26. Shuntsurveillance en shuntocclusie: een analyse naar effectiviteit en verpleegkundige werkdruk  
*E. Wijnen*  
Acad ziekenhuis Maastricht
- 14.50-15.05 27. Ultrasonic-site makes difficult canulation right  
*M. ter Meer*  
Sint Lucas Andreas Ziekenhuis
- 15.05-15.20 28. De buttonhole-techniek, een casus  
*A.M. Verhallen, B.C. van Jaarsveld*  
Dianet Dialysecentra
- 15.20-15.35 29. Verkorting van afdruktijd na hemodialyse m.b.v. Microporeuse Polysacharide Partikels (MPP) (Bleed-X)  
*K. van Riel, G.M.T. de Jong*  
Albert Schweitzer Ziekenhuis, Dordrecht
- 15.35-15.50 PAUZE Kempen / Genderhal**
- 15.50-17.38 Wetenschappelijke Sessie NfN IV / Zaal 80**  
voorzitters: *G. Ligtenberg en L.B. Hilbrands*
- 15.50-16.02 30. Tissue chimerism occurs in kidneys of the normal female population  
*I.C.L. Kremer Hovinga, M. Koopmans, J.J. Baelde, D. Hoogervorst, E. de Heer, J.A. Bruijn, I.M. Bajema*  
Leiden University Medical Center
- 16.02-16.14 31. Myeloid related proteins 8 and 14, B cell markers, and Lung surfactant protein-C in acute rejection of renal allografts in relation to chronic allograft nephropathy  
*M. Eikmans<sup>1</sup>, M.C. Roos-van Groningen<sup>1</sup>, Y.W.J. Sijpkens<sup>2</sup>, J. Erchen<sup>3</sup>, H.J. Baelde<sup>1</sup>, J.W. de Fijter<sup>2</sup>, L.C. Paul<sup>2</sup>, E. de Heer<sup>1</sup>, J.A. Bruijn<sup>1</sup>*  
<sup>1</sup>Dpt. of Pathology, LUMC, Leiden, <sup>2</sup>Dpt. of Nephrology, LUMC, Leiden, <sup>3</sup>Institute of Dermatology, Münster
- 16.14-16.26 32. AUC-guided dosing of tacrolimus versus cyclosporine: superior rejection rates at the cost of high incidence of post transplant diabetes mellitus  
*E.M. Scholten<sup>1</sup>, A. Rowshani<sup>2</sup>, S. Florquin<sup>3</sup>, I. Bajema<sup>4</sup>, J. Surachno<sup>2</sup>, F. Bemelman<sup>2</sup>, L.C.Paul<sup>1</sup>, I. ten Berge<sup>2</sup>, J.W. de Fijter<sup>1</sup>*  
<sup>1</sup>Nephrology, LUMC, Leiden, <sup>2</sup>Nephrology, AMC, Amsterdam, <sup>3</sup>Pathology, AMC, Amsterdam, <sup>4</sup>Pathology, LUMC, Leiden
- 16.26-16.38 33. No difference in renal fibrosis in serial renal biopsies between auc-guided dosing of cyclosporine and tacrolimus based immunosuppression: a randomized trial  
*A.T. Rowshani<sup>1</sup>, E.M. Scholten<sup>2</sup>, I. M. Bajema<sup>3</sup>, F. Bemelman<sup>1</sup>, J. Surachno<sup>1</sup>, M. Mallat<sup>2</sup>, L. C. Paul<sup>2</sup>, J. W. de Fijter<sup>2</sup>, I. ten Berge<sup>1</sup>, Sandrine Florquin<sup>4</sup>*  
<sup>1</sup>Nephrology, AMC, Amsterdam, <sup>2</sup>Nephrology, LUMC, Leiden, <sup>3</sup>Pathology LUMC, <sup>4</sup>Pathology, AMC, Amsterdam
- 16.38-16.50 34. New immunosuppressant FK778 shows efficacy in renal TX  
*JP van Hooff, M.H.L. Christiaans on behalf of the European FK 778 Kidney Transplant Study Group*

- University hospital Maastricht
- 16.50-17.02 35. Long-term efficacy and safety of steroid-withdrawal in tacrolimus-treated renal transplant recipients: results of a 3-year follow-up  
*M.H.L. Christiaans, J.P. van Hooff on behalf of the Thomas-trial study group*  
University hospital Maastricht
- 17.02-17.14 36. Controlled study to reduce the immunosuppressive load after kidney transplantation guided by donor specific CTLp monitoring  
*J. van de Wetering<sup>1</sup>, B.J. van der Mast<sup>1</sup>, P. de Kuiper<sup>1</sup>, N.M. van Besouw<sup>1</sup>, J. Rischen-Vos<sup>1</sup>, J.N.M. IJzermans<sup>2</sup>, W. Weimar<sup>1</sup>*  
<sup>1</sup>Internal Medicine, Erasmus MC, Rotterdam, <sup>2</sup>General Surgery, Erasmus MC, Rotterdam
- 17.14-17.26 37. Over-immunosuppression after HLA-identical living-related kidney transplantation  
*J.H. Gerrits, S.M. Postma, L.M.B. Vaessen, J. van de Wetering, J. Rischen, B.J. van der Mast, W. Weimar, N.M. van Besouw*  
Internal Medicine, Erasmus MC, Rotterdam
- 17.26-17.38 38. Non-heart-beating kidney transplantation from donors aged 65 years and older: a single center experience  
*S. Schaefer, M. Christiaans, J. van Hooff, W.A. Buurman, L.W.E. van Heurn*  
University Hospital Maastricht
- 15.50-17.38 Wetenschappelijke Sessie NfN V / Diezahal**  
*voorzitters: R. Huisman en K. Leunissen*
- 15.50-16.02 39. Risk factors for decline in renal function in predialysis patients  
*N. Voormolen<sup>1</sup>, J.G. van Manen<sup>1</sup>, Y.W. Sijpkens<sup>1</sup>, R.M. Huisman<sup>2</sup>, E.W. Boeschoten<sup>3</sup>, F. van der Sman-de Beer<sup>1</sup>, F.W. Dekker<sup>1</sup>, PREPARE study group<sup>3</sup>*  
<sup>1</sup>LUMC, Leiden, <sup>2</sup>AZG, Groningen, <sup>3</sup>Hans Mak Instituut, Naarden
- 16.02-16.14 40. Association of the ACE I/D polymorphism with mortality in a prospective study of incident dialysis patients  
*F. van der Sman-de Beer<sup>1</sup>, C. Verhagen<sup>2</sup>, S.M. Rombach<sup>3</sup>, P. Boorsma<sup>4</sup>, J.G. van Manen<sup>1</sup>, J.C. Korevaar<sup>3</sup>, E.W. Boeschoten<sup>2</sup>, R.T. Krediet<sup>5</sup>, G.J. Navis<sup>6</sup>, F.W. Dekker<sup>1</sup>*  
<sup>1</sup>LUMC, Clinical Epidemiology, <sup>2</sup>Hans Mak Institute, Naarden, <sup>3</sup>AMC, Clin. Epidemiology & Biostatistics, <sup>4</sup>AMC, Clinical Genetics, <sup>5</sup>AMC, Nephrology, <sup>6</sup>AZG, Nephrology
- 16.14-16.26 41. Serum calcium, phosphate and PTH levels in Dutch dialysis patients; do they meet the K/DOQI criteria?  
*J.C. Korevaar<sup>1</sup>, F.W. Dekker<sup>2</sup>, E.W. Boeschoten<sup>3</sup>, R.T. Krediet<sup>1</sup>, W.J. Bos<sup>4</sup>*  
<sup>1</sup>AMC, <sup>2</sup>LUMC, <sup>3</sup>Hans Mak Instituut, <sup>4</sup>St Antonius ziekenhuis
- 16.26-16.38 42. Oral dryness and thirst are associated with interdialytic weight gain in patients on hemodialysis  
*Casper P. Bots<sup>1</sup>, Henk S. Brand<sup>1</sup>, Enno C.I. Veerman<sup>1</sup>, Marianne Valentijn-Benz<sup>1</sup>, Barbara M. Van Amerongen<sup>1</sup>, Rob M. Valentijn<sup>2</sup>, Pieter F. Vos<sup>3</sup>, Joost A. Bijlsma<sup>4</sup>, Piet M. ter Wee<sup>5</sup>, Arie V. Nieuw Amerongen<sup>1</sup>*  
<sup>1</sup>Dept. Dental Basic Sci., ACTA, Amsteden, <sup>2</sup>Dept. Internal Medicine, RKZ, Den Haag, <sup>3</sup>DIANET Dialysis Centers, Utrecht, <sup>4</sup>DIANET Dialysis Centers, Amsterdam, <sup>5</sup>Dept. Nephrology, VUMC, Amsterdam
- 16.38-16.50 43. The effect of novel methodologies on hemodynamics and sodium balance in hypotension prone hemodialysis (HD) patients  
*J. Aalten<sup>1</sup>, K. Moret<sup>1</sup>, W. van den Wall Bake<sup>1</sup>, P. Gerlag<sup>1</sup>, C. Beerenhout<sup>1</sup>, F. van der Sande<sup>2</sup>, J. Kooman<sup>2</sup>*  
<sup>1</sup>Maxima Medisch Centrum Veldhoven, <sup>2</sup>Academisch Ziekenhuis Maastricht
- 16.50-17.02 44. Effects of pre-dilution on-line hemofiltration (HF) on cardiovascular and nutritional state and quality of life (QOL): results of a randomized study

*C.M. Beerenhout<sup>1</sup>, A.J. Luik<sup>2</sup>, S. Jeukens-Mertens<sup>2</sup>, V. Renette<sup>1</sup>, F.M. van der Sande<sup>1</sup>, K.M. Leunissen<sup>1</sup>, J.P. Kooman<sup>1</sup>*

<sup>1</sup>Academisch Ziekenhuis Maastricht, <sup>2</sup>Viecuri Ziekenhuizen Venlo

- 17.02-17.14 45. Plasma markers of endothelial dysfunction are influenced by the administered peritoneal dialysis regimen (NEPP or standard)  
*C. le Poole<sup>1</sup>, F.J. van Ittersum<sup>1</sup>, M.C. Weijmer<sup>1</sup>, R.M. Valentijn<sup>2</sup>, P.M. ter Wee<sup>1</sup>, C.G. Schalkwijk<sup>3</sup>,*  
<sup>1</sup>VUmc (Nephrology) Amsterdam, <sup>2</sup>Rode Kruis Ziekenhuis (Interne) Den Haag, <sup>3</sup>VUmc (Clinical Chemistry) Amsterdam
- 17.14-17.26 46. Peritoneal Dialysis Fluids (PDF) containing a mixture of amino-acids (AA) and glucose improve protein metabolism in CCPD patients : Dialysate as food  
*Tjong HL<sup>1</sup>, van de Berg JW<sup>2</sup>, Wattima JLD<sup>2</sup>, Rietveld T<sup>2</sup>, van Dijk L<sup>1</sup>, van de Wiel A<sup>3</sup>, van Egmond A<sup>3</sup>, Swart GR<sup>2</sup>, Fieren MWJA<sup>1</sup>*  
<sup>1</sup>ErasmusMC, section of nephrology, <sup>2</sup>ErasmusMC, section of metabolic and vascular medicine, <sup>3</sup>ErasmusMC, dept. of dietetics
- 17.26-17.38 47. Polymicrobial peritonitis and acute abdominal events in patients on peritoneal dialysis  
*R. Wijering, L. Straathof-Galema, W.A.H. Koning-Mulder, H.S. Brink, R.M.L. Brouwer*  
Interne Geneeskunde, MST, Enschede
- 15.50-17.38 Wetenschappelijke Sessie NfN VI / Baroniezaal**  
*voorzitters: G.J. Navis en J. Aten*
- 15.50-16.02 48. ATP depletion and increased oxidised glutathione in cultured cystinotic fibroblasts  
*E.Levtchenko<sup>1</sup>, M.Wilmer<sup>2</sup>, A. de Graaf-Hess<sup>2</sup>, J. Koenderink<sup>3</sup>, H. Blom<sup>2</sup>, L. van den Heuvel<sup>1</sup>, L. Monnens<sup>1</sup>*  
<sup>1</sup>Dept of Paediatric Nephrology, <sup>2</sup>Laboratory of Paediatrics & Neurology, <sup>3</sup>Dept of Biophysical Chemistry, UMCN
- 16.02-16.14 49. Characterization of a murine renal distal convoluted tubule cell line (mpkDCT) to study transcellular calcium transport  
*R.J.W. Diepens<sup>1</sup>, E. de Dekker<sup>1</sup>, M. Bens<sup>2</sup>, A.F. Weidema<sup>1</sup>, A. Vandewalle<sup>2</sup>, R.J.M. Bindels<sup>1</sup>, J.G.J. Hoenderop<sup>1</sup>*  
<sup>1</sup>UMC Nijmegen, The Netherlands, <sup>2</sup>INSERM, Paris, France
- 16.14-16.26 50. Heterogeneity of glycosaminoglycans in the normal human kidney as detected by single chain antibodies  
*J.F.M. Lensen<sup>1</sup>, A. Rops<sup>2</sup>, T.J.M. Wijnhoven<sup>1</sup>, J. van der Vlag<sup>2</sup>, J.H.M. Berden<sup>2</sup>, L.P.W.J. van den Heuvel<sup>3</sup>, W.F.J. Feitz<sup>4</sup>, T.H. van Kuppevelt<sup>1</sup>*  
<sup>1</sup>Matrix Biochemistry, UMC Nijmegen, <sup>2</sup>Nephrology, UMC Nijmegen, <sup>3</sup>Pediatrics, UMC Nijmegen, <sup>4</sup>Urology, UMC Nijmegen
- 16.26-16.38 51. Pro-inflammatory cytokines induce a differential expression of heparan sulfate proteoglycans by conditionally immortalized mouse glomerular endothelial cells  
*A. Rops<sup>1</sup>, J. van der Vlag<sup>1</sup>, C. Jacobs<sup>1</sup>, H. Dijkman<sup>2</sup>, J. Lensen<sup>3</sup>, T. Wijnhoven<sup>3</sup>, L. van den Heuvel<sup>4</sup>, T. van Kuppevelt<sup>3</sup>, J. Berden<sup>1</sup>*  
<sup>1</sup>Division of Nephrology, UMC Nijmegen, <sup>2</sup>Department of Pathology, UMC Nijmegen, <sup>3</sup>Department of Biochemistry, NCMLS, <sup>4</sup>Department of Pediatrics, UMC Nijmegen
- 16.38-16.50 52. Histone acetylation is associated with apoptosis and systemic lupus erythematosus  
*J.W. Dieker<sup>1</sup>, C.W. Jacobs<sup>1</sup>, S. Muller<sup>2</sup>, J.H. Berden<sup>1</sup>, J. van der Vlag<sup>1</sup>*  
<sup>1</sup>Division of Nephrology, UMC Nijmegen, <sup>2</sup>CNRS, Strasbourg, France
- 16.50-17.02 53. Selective delivery of drugs into activated endothelial cells in anti-GBM glomerulonephritis mice model  
*S.A. Ásgeirsdóttir<sup>1</sup>, R.J. Kok<sup>2</sup>, J.A.A.M. Kamps<sup>1</sup>, H. van Goor<sup>3</sup>, P. Heeringa<sup>4</sup>, P. Klok<sup>3</sup>, N. Werner<sup>1</sup>, H. Moorlag<sup>1</sup>, C.G.M. Kallenberg<sup>5</sup>, G. Molema<sup>1</sup>*

<sup>1</sup> Dept of Pathology & Laboratory Medicine, <sup>2</sup> Dept of Pharmacokinetic and Drug Delivery, <sup>3</sup> Dept of Pathology, University Hospital, <sup>4</sup> Dept of Clinical and Experimental Immunology, <sup>5</sup> Dept of Clinical Immunology, University Hospital Groningen

- 17.02-17.14 54. Renal targeting of captopril by lysozyme enhances its antiproteinuric effect in adriamycin induced nephrosis  
*W.A.K.M. Windt<sup>1</sup>, J. Prakash<sup>2</sup>, R.J. Kok<sup>2</sup>, F. Moolenaar<sup>2</sup>, C.A. Kluppel<sup>1</sup>, D. de Zeeuw<sup>1</sup>, R.P.E. van Dokkum<sup>1</sup>, R.H. Henning<sup>1</sup>*  
<sup>1</sup> Clinical Pharmacology, RuG, <sup>2</sup> Pharmacokinetics and Drug Delivery, RuG
- 17.14-17.26 55. Renal function of wt1-heterozygous mice is impaired in the absence of histological abnormalities  
*R. Masereeuw<sup>1</sup>, A. Ijpenberg<sup>2</sup>, G.J. Grutters<sup>3</sup>, H.B. Dijkman<sup>4</sup>, F.G.M. Russel<sup>1</sup>, J.H. Jansen<sup>5</sup>, N.D. Hastie<sup>2</sup>, A.L. Menke<sup>5</sup>*  
<sup>1</sup> Dept. Pharmacology and Toxicology, UMCN, <sup>2</sup> MRC Human Genetics Unit, Edinburgh, UK, <sup>3</sup> Central Animal Laboratory, UMCN, <sup>4</sup> Dept. Pathology, UMCN, <sup>5</sup> Central Hematology Laboratory, UMCN
- 17.26-17.38 56. Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease  
*Irma S. Lantinga-van Leeuwen<sup>1</sup>, Hans G. Dauwerse<sup>1</sup>, Hans J. Baelde<sup>2</sup>, Wouter N. Leonhard<sup>1</sup>, Annemieke van de Wal<sup>2</sup>, Marco C. de Ruiter<sup>3</sup>, Martijn H. Breuning<sup>1</sup>, Emile de Heer<sup>2</sup>, Dorien J.M. Peters<sup>1</sup>*  
<sup>1</sup> LUMC, Dept. of Human Genetics, <sup>2</sup> LUMC, Dept. of Pathology, <sup>3</sup> LUMC, Dept. of Anatomy & Embryology
- 15.50-17.35 Paramedische sessie II / Brabantzaal**  
*voorzitters: B. de Graaf en Y. de Koter*
- 15.50-16.05 57. Intensieve verpleegkundige begeleiding leidt tot een sterke verbetering van de fosfaatregulatie: resultaten van een korte termijnstudie  
*A. Hahnraaths-Aarts, M. Hertog-Custers*  
AzM
- 16.05-16.20 58. Voedingsdagboeken in de praktijk bij hemodialysepatiënten: vergelijk tussen 3-daagse en 7-daagse methode  
*L. Hover<sup>1</sup>, N. Cox<sup>1</sup>, C. Beerenhout<sup>2</sup>, L. Klaassen<sup>3</sup>,*  
<sup>1</sup> Academisch ziekenhuis Maastricht, <sup>2</sup> Maxima medisch centrum, Veldhoven, <sup>3</sup> Viecuri medisch centrum, locatie Venlo
- 16.20-16.35 59. Voorlichtingsgat  
*J.P.W. Neyndorff-Meijer<sup>1</sup>, V. Sauv  <sup>1</sup>, N. Kleijn<sup>1</sup>*  
Catharina ziekenhuis Eindhoven
- 16.35-16.50 60. Verpleegkundige aspecten van on-line hemofiltratie (HF)  
*V. Renette*  
AzM
- 16.50-17.05 61. Een flowchart voor bloedvolume afhankelijke ultrafiltratiecontrole  
*S. Maleki, R. Visser, M.C. Roggekamp*  
Dianet Dialysecentra, Amsterdam
- 17.05-17.20 62. Thuishemodialyse bij kinderen  
*W. Jansen*  
Dianet te Utrecht
- 17.20-17.35 63. Het gebruik van een bi-directionele modem tussen de HomeChoice PRO en PD Link levert een tijds winst op voor verpleegkundigen en pati nten waardoor de verpleegkundige sneller en effici nter inzicht krijgt in de behandeling  
*T. Klatt- Meyer*  
Rijnland Ziekenhuis Leiderdorp

**17.45-18.30** **Plenair: Special invited lecture / Diezehal**  
*voorzitter: P. Blankestijn*  
H. Galjaard (Rotterdam)  
Moderne gentechnologie en maatschappelijke acceptatie

**18.30-19.30** **Borrel / Kempen en Genderhal**

**19.30-21.30** **Buffet / Beneluxhal**

**21.30-.....** **Feestelijk programma / Brabantzaal**  
café open tot 01.00 uur

## VRIJDAG 26 MAART 2004

- 09.00-10.45 Fundamenteel Wetenschappelijk Symposium II / Diezehal**  
**“New insights into the genetics of blood pressure regulation”.**  
*voorzitters: G.J. Navis en R.J.M. Bindels*
- 09.00-09.30 G.J. Navis (Groningen)  
Unravelling the complex phenotype: the physiological approach
- 09.35-10.05 C. Chatziantoniou (Paris, FR)  
Novel insights into the mechanisms of progression and regression of renal fibrosis
- 10.10-10.40 R. Kreutz (Berlijn, DE)  
Molecular genetics of hypertension-induced renal damage by an experimental approach.
- 09.00-10.20 Multidisciplinaire Workshop / Brabantzaal**  
**“Rechten en plichten van patiënt en behandelaar”**  
*voorzitter: V. Deconinck*  
Interactieve paneldiscussie
- 10.20-10.50 Presentaties van klinische trials / Brabantzaal**  
*voorzitter: F. van Ittersum*
- Lupus-nefritis – G. Ligtenberg  
Aza-ANCA studie – J. Sanders  
STAR – J. Beutler  
AURORA – J. Beutler  
PREPARE – Y. Sijpkens  
CONTRAST – L. Penne  
CIMINO – H. Huijbregts
- 10.50-11.10 PAUZE / Kempen en Genderhal**
- 10.45-13.00 Algemene Ledenvergadering Vereniging Maatschappelijk Werk Nefrologie / Baroniezaal**
- 11.10-12.30 Uitreiking prijzen en proefschriftpresentaties / Brabantzaal**  
*voorzitters: L.B. Hilbrands en P.J. Blankestijn*
- 11.10-11.25 Presentatie proefschrift: Intra- and extracellular factors involved in the trafficking of the aquaporin-2. B. van Balkom, Nijmegen
- 11.25-11.40 Presentatie proefschrift: Chronic rejection in renal transplantation. Y. Sijpkens, Leiden
- 11.40-11.55 Presentatie proefschrift: Long-term complications of immunosuppressive therapy after renal transplantation. R. de Sévaux, Nijmegen
- 11.55-12.10 RENINE: Stand van zaken
- 12.10-12.25 Uitreiking van prijzen voor de beste abstracts in de categorieën klinisch, experimenteel en paramedisch
- 12.25-12.30 Uitreiking NSN-NfN proefschriftprijs 2003 door een vertegenwoordiger van de jury

- 12.30-13.30 LUNCH / Kempen en Genderhal**
- 12.30-13.30 Vergadering Plenaire Visitatie Commissie / Brabantzaal**
- 13.30-14.30 Plenair: Special Invited Lectures / Diezehal**  
**“Mogelijkheden om het donorpotentieel voor niertransplantatie te verhogen”**  
*voorzitter: L.B. Hilbrands*
- 13.30-14.00 W. Weimar (Rotterdam)  
 Donatie bij leven
- 14.00-14.30 A.J. Hoitsma (Nijmegen)  
 Non-heart-beating donoren
- 14.35-15:59 Wetenschappelijke Sessie NfN VII / Baroniezaal**  
*voorzitters: W. Rensma en E. de Heer*
- 14.35-14.47 64. Lack of AVP-induced phosphorylation of the Aquaporin-2 mutants AQP2-R254L and AQP2-R254Q explains dominant Nephrogenic Diabetes Insipidus  
*Paul JM Savelkoul<sup>1</sup>, Fabrizio de Mattia<sup>1</sup>, Erik-Jan Kamsteeg<sup>1</sup>, Irene BM Konings<sup>1</sup>, Carel H. van Os<sup>1</sup>, Peter van der Sluijs<sup>2</sup>, Alexander Oksche<sup>3</sup>, Gary Robertson<sup>4</sup>, Peter MT Deen<sup>1</sup>*  
<sup>1</sup>UMC Nijmegen, <sup>2</sup>Dept Cell Biology, Utrecht, <sup>3</sup>Forsch.linst. Mol. Pharm, Berlin, <sup>4</sup>Northwestern University, Chicago, USA
- 14.47-14.59 65. Influence of the level of hyperglycaemia on renal microvasculature reactivity during experimental diabetes mellitus type 1  
*M.H. Roos<sup>1</sup>, W.F. van Rodijnen<sup>1</sup>, P.M. ter Wee<sup>2</sup>, A.A. van Lambalgen<sup>1</sup>, G.J. Tangelder<sup>1</sup>*  
<sup>1</sup>Lab. for Physiology, VUMC, <sup>2</sup>Dept. of Nephrology, VUMC
- 14.59-15.11 66. Nitric oxide-dependent and independent transcriptional responses to high shear stress in endothelial cells  
*Branko Braam<sup>1</sup>, Remmert de Roos<sup>1</sup>, Frank Holstege<sup>2</sup>, Hans Bluysen<sup>1</sup>, Jaap Joles<sup>1</sup>, Hein Koomans<sup>1</sup>*  
<sup>1</sup>UMC Utrecht, Afd. Nierziekten, <sup>2</sup>UMC Utrecht, Genomics Afd.
- 15.11-15.23 67. Brief perinatal inducible NOS inhibition and tetrahydrobiopterin (BH4) supplementation both reduce blood pressure (BP) in female spontaneously hypertensive rats (SHR)  
*M.P.M. Koeners, S. Racasan, R. Goldschmeding, H.A. Koomans, B. Braam, J.A. Joles*  
 University Medical Center, Utrecht
- 15.23-15.35 68. Transcriptional responses to injury in renal cortex of rats with chronic NO synthase inhibition are ameliorated by vitamin E – a microarray study  
*S. Wesseling<sup>1</sup>, F.C.P. Holstege<sup>2</sup>, H.A. Koomans<sup>1</sup>, J.A. Joles<sup>1</sup>, B. Braam<sup>1</sup>*  
<sup>1</sup>UMC Utrecht - Afd. Nierziekten, <sup>2</sup>UMC Utrecht - Genomics Afd.
- 15.35-15.47 69. Arterial compliance can be normalized in hypertensive chronic kidney disease patients  
*J. Neumann, G. Ligtenberg, A. Abrahams, H.A. Koomans, P.J. Blankestijn*  
 Nephrology, University Hospital, Utrecht
- 15.47-15.59 70. Eprosartan combined with moxonidine normalizes sympathetic hyperactivity in hypertensive chronic renal failure patients  
*J. Neumann<sup>1</sup>, G. Ligtenberg<sup>1</sup>, L. Oey<sup>2</sup>, H.A. Koomans<sup>1</sup>, P.J. Blankestijn<sup>1</sup>*  
<sup>1</sup>Nephrology, University Hospital, Utrecht, <sup>2</sup>Neurophysiology, University Hospital, Utrecht

**14.35-15:59 Wenschappelijke Sessie NfN VIII / Diezehal**

*voorzitters: H. van Goor en L. Hilbrands*

- 14.35-14.47 71. VEGF mediates endothelial activation and chemokine production and is functional in allograft rejection  
*M..E.J.Reinders<sup>1,2</sup>, M. Sho<sup>1</sup>, C.S.Geehan<sup>1</sup>, A.M.Luster<sup>1</sup>, M.H. Sayegh<sup>1</sup>, D.M. Briscoe<sup>1</sup>*  
<sup>1</sup> Harvard Medical School, Boston, USA, <sup>2</sup> Leids Universitair Medisch Centrum
- 14.47-14.59 72. Vascular endothelial growth factor gene polymorphism influences renal graft survival in living donor transplants  
*F. Lemos<sup>1</sup>, W. Mol<sup>1</sup>, J. Roodnat<sup>1</sup>, A. Uitterlinden<sup>1</sup>, J. IJzermans<sup>2</sup>, W. Weimar<sup>1</sup>, C. Baan<sup>1</sup>*  
<sup>1</sup> Internal Medicine, Erasmus MC - Rotterdam, <sup>2</sup> Surgery, Erasmus MC – Rotterdam
- 14.59-15.11 73. Renal expression of heat-shock proteins after brain-death induction in rats  
*E.M. Bos<sup>1</sup>, T.A. Schuurs<sup>1</sup>, M. Kraan<sup>1</sup>, P.J. Ottens<sup>1</sup>, M.M.E.D. van den Eijnden<sup>1</sup>, H.G.D. Leuvenink<sup>1</sup>, H.H. Kampinga<sup>2</sup>, H. van Goor<sup>1</sup>, R.J. Ploeg<sup>1</sup>*  
<sup>1</sup> Academisch Ziekenhuis Groningen, <sup>2</sup> Rijksuniversiteit Groningen
- 15.11-15.23 74. P-glycoprotein does not prevent apoptosis in renal proximal tubule cells  
*A.L.A. Sesink<sup>1</sup>, R. Masereeuw<sup>1</sup>, R.A. Raymakers<sup>2</sup>, F.G.M. Russel<sup>1</sup>*  
<sup>1</sup> Dept. Pharmacology-Toxicology, UMCN, <sup>2</sup> Dept. Haematology, UMCN
- 15.23-15.35 75. Redox-active iron plays a crucial role in the pathophysiology of renal ischemia-reperfusion injury  
*B. de Vries<sup>1</sup>, S. Schaefer<sup>1</sup>, J. Parkkinen<sup>2</sup>, L.W.E. van Heurn<sup>1</sup>, W.A. Buurman<sup>1</sup>*  
<sup>1</sup> Academic Hospital Maastricht, <sup>2</sup> FRC, Helsinki, Finland
- 15.35-15.47 76. CD44-mediated granulocyte migration contributes to renal ischemia reperfusion injury  
*K.M.A. Rouschop, J.J.T.H. Roelofs, N.Claessen, S.T. Pals, J.J. Weening, S. Florquin*  
Academic medical center, Amsterdam
- 15.47-15.59 77. Stem cell factor and granulocyte-colony stimulating factor accelerate renal recovery after ischemia/reperfusion injury  
*G. Stokman, J.C. Leemans, N. Claessen, J.J. Weening, S. Florquin*  
Department of Pathology, AMC, Amsterdam

**14.35-16:00 Paramedische sessie III / Brabantzaal**

*voorzitters: R. Tollenaar en C. Broeders*

- 14.35-14.50 78. Klinische paden  
*E. Pol, C. Oudehand*  
Dialysecentrum Almelo
- 14.50-15.05 79. Psychosociale en maatschappelijke zorg, een verpleegkundige taak?  
*A.M.A.van Schoubroeck*  
Laurentius ziekenhuis Roermond
- 15.05-15.20 80. Richtlijnontwikkeling ter bevordering van adequaat zelfmanagement bij hemodialysepatiënten met betrekking tot de vochtbeperking: een behoeftegestuurde benadering  
*M.J.M. Litjens<sup>1</sup>, S.W.M. Weldam<sup>2</sup>, M.H.F. Grypdonck<sup>2</sup>*  
<sup>1</sup> UMCN en Verplegingswetenschap UMCU, <sup>2</sup> Verplegingswetenschap UMCU
- 15.20-15.35 81. Goed voorgelicht de behandeling in zicht!!  
*F. Peeters-Op het Roodt, K. Bex*  
VieCuri Medisch Centrum
- 15.35-15.50 82. Methodisch verplegen op de dialyseafdeling  
*C.H.A. Matheeuwsen- van Limpt*  
Catharina Ziekenhuis Eindhoven

15.50-16.05 83. Probleemonderzoek door verpleegkundigen. Over sperziebonen en aansluitsets.  
*M.H.A. Jordens*  
UMC St. Radboud, Nijmegen

**16.05-16.45 Hapje en drankje in de foyer**